Synopsis: In this episode of the Biotech2050 podcast, David Kirn, CEO of 4D Molecular Therapeutics, shares invaluable insights for aspiring entrepreneurs in the biotech industry. Kirn discusses the development of his company's platform that integrates gene therapy and directed evolution to create innovative treatments for genetic diseases. By utilizing directed evolution, 4D Molecular Therapeutics has been able to invent an AAV vector that achieves safe and effective gene expression in the retina, targeting rare genetic diseases initially and subsequently expanding to larger markets. Kirn emphasizes the importance of balancing a strong platform with diverse product opportunities to decrease risk and increase the probability of success in the biotech landscape. Kirn's expertise and experience provide a compelling narrative that sheds light on the vital aspects of biotech entrepreneurship. Kirn emphasizes the importance of balancing a strong platform with diverse product opportunities to decrease risk and increase the probability of success in the biotech landscape. The episode delves into the tension between platform and product focus, offering guidance on fundraising and the regional dynamics of biotech investment. Kirn's expertise and experience provide a compelling narrative that sheds light on the vital aspects of biotech entrepreneurship, making this episode a must-listen for academic entrepreneurs looking to navigate the complexities of biotech investment and build traction in the industry. Biography: David Kirn, MD, is our co-founder and has served as our Chief Executive Officer since our inception in 2013. Dr. Kirn is also Adjunct Professor of Bioengineering and Molecular & Cellular Biology at UC Berkeley. Over his 30 year career, Dr. Kirn has co-founded and been CEO of four viral vector-based genetic medicines companies, three of which to date were either acquired or went public. Dr. Kirn also held senior clinical research and development positions at Onyx Pharmaceuticals (VP) and Celgene (SVP), and was a senior advisor to Novartis, Bayer, Pfizer, Biogen and others in the genetic medicines field. Dr. Kirn received a BA in Physiology (Departmental Citation; Phi Beta Kappa) from UC Berkeley in 1985, an MD (Alpha Omega Alpha) from UC San Francisco Medical School in 1989 and completed internal medicine residency training at Harvard Medical School, Brigham and Women’s Hospital (including a term as Chief Medical Resident at affiliated VA hospital). He has also completed hematology-oncology and clinical research fellowships at UC San Francisco and completed a certificate of business excellence from the Haas Business School at UC Berkeley. In 2013, he was awarded the Johnson & Johnson Entrepreneur Innovator award from the J&J Innovation Center.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related